Circulating Osteoclast Precursors as Markers of Bone Resorption in Inflammatory Arthritis

Brief Description
Applications:
The invention is a cell culture assay of a subject's circulating peripheral blood mononuclear cells (PBMC) to determine the number of osteoclast precursors among those cells.  This technology can determine whether inflammatory arthritis patients are at increased risk for bone erosion and can be used to test the efficacy of therapeutic agents in inflammatory arthritis (diagnosis and monitoring of therapy) and may be useful in other rheumatoid and autoimmune conditions such as Crohn?s disease, psoriasis, rheumatoid arthritis, and ankylosing spondylitis.

Advantages:
There are currently no accepted methods for early evaluation of and prediction of which patients are at the most risk for erosive bone disease, and there is currently no method that can demonstrate early in the course of therapy whether the therapeutic approach will work.  This technology has the advantage of using a biomarker that is correlated to a later outcome of therapy.
Patent Information:
Title Country Patent No. Issued Date
Methods and Compositions Related to Joint Inflammation Diseases United States 7,807,389 10/5/2010
Category(s):
Diagnostic
For Information, Contact:
Weimin Kaufman
Licensing Manager
University of Rochester
585.276.6608
weimin.kaufman@rochester.edu
Inventors:
Christopher Ritchlin
Sally Haas
Edward Schwarz
Keywords:
Anti-inflammatory
in vivo
Musculoskeletal
Autoimmune
Inflammation
Therapy